Potentiation of vincristine cytotoxicity by rubiginone B1 and piperafizine A in human Moser and K562 cells--mode of action.
Ogasawara
M
M
Bristol-Myers Squibb Research Institute, Tokyo, Japan.
Hasegawa
M
M
Hamagishi
Y
Y
Kamei
H
H
Oki
T
T
D000880:Anthraquinones / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002277:Carcinoma; D015179:Colorectal Neoplasms; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006801:Humans; D007938:Leukemia; D010879:Piperazines / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014750:Vincristine / Q000494:pharmacology*; D000095602:Angucyclines and Angucyclinones
D000880:Anthraquinones; D000900:Anti-Bacterial Agents; D010879:Piperazines; D014750:Vincristine; C073563:rubiginone B1; D000095602:Angucyclines and Angucyclinones; C066103:piperafizine A